Lorentzson 1990.

Methods	Setting: multicentre study Sweden & Norway, hospital outpatient clinic Randomisation: yes, method not stated Allocation concealment: unclear Design: parallel Intervention period: 6 weeks Masking: double blind Excluded: not stated Withdrawals: stated Baseline characteristics: comparable Jadad score=3
Participants	103 adults: 58M 45F Age range: 16‐59 years Inclusion criteria: Mild asthma Use of 35 puffs rescue beta2‐agonist during run in week and mean variation of 10‐30% in PEFR PEFR (% predicted) 75 or greater Exclusion criteria: Use of oral or inhaled steroids Serious co‐existent disease Respiratory infection or acute asthma exacerbation in last month
Interventions	BUD: 1. 100 mcg 1pf 2xdaily (200 mcg/d) 2. 200 mcg 1pf 2xdaily (400 mcg/d) Delivery device: MDI+spacer Placebo: 1 pf 2xdaily via MDI+spacer
Outcomes	Change in morning PEFR compared to baseline Change in evening PEFR compared to baseline Change in daily use beta2 agonists compared to baseline Daily asthma symptom score Withdrawal due to asthma exacerbation Incidence of oropharyngeal side effects Incidence of oropharyngeal Candidasis
Notes	No reply from author to clarify details of randomisation method. Two dosage schedules are used in this trial. Only data for those patients assigned to 400 mcg/d has been used in the meta‐analysis
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	B ‐ Unclear